Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.
Also called NCT05712200
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,500 participants
- Registry
-
NCT05712200 -
2023-503224-66-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Peru, Philippines, Poland, Puerto Rico, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05712200. Randomized; double masking; primary purpose treatment. Start 2022-12-27 (actual); primary completion 2027-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- Acronym
- LILAC-TIMI 76
- Condition
- Atrial Fibrillation (AF)
- Intervention (Biological)
- Abelacimab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Anthos Therapeutics, Inc.
- Collaborator
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05712200- Content hash
42fbfb3b83f59b330a753c574c3bf262b811c57a2e43200302971c1a28272769